Loading...
How to manage atrial fibrillation secondary to ibrutinib
Essa, H. Lodhi, Taha Dobson, R. Wright, D. Lip, G. Y. H.
Essa, H.
Lodhi, Taha
Dobson, R.
Wright, D.
Lip, G. Y. H.
Citations
Altmetric:
Abstract
Atrial fibrillation (AF) is the most common cardiac
arrhythmia and a significant cause of
cardiovascular morbidity and mortality
worldwide (1). Ibrutinib is a covalent irreversible inhibitor
of Bruton’s tyrosine kinase (BTK) used in the
treatment of B-cell cancers such as chronic lymphocytic
leukemia and mantle cell lymphoma. It is estimated
that up to 16% of patients develop ibrutinibinduced
AF, which can be a therapy-limiting side effect.
The mechanisms are not clear but may relate to
direct inhibition of BTK, which is expressed in cardiac
tissue (2). In this primer, we use a clinical case of a
patient with chronic lymphocytic leukemia to demonstrate
the challenges and management considerations
of AF secondary to ibrutinib.
Description
Date
2021
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 517.81 KB
Keywords
Type
Other
Citation
Essa H, Lodhi T, Dobson R, Wright D, Lip GYH. How to Manage Atrial Fibrillation Secondary to Ibrutinib. JACC: CardioOncology. 2021 Mar;3(1):140–4.